Trial of SAGE-217 in patients with major depressive disorder

Authors

Handan Gunduz-Bruce, Sage Therapeutics
Christopher Silber, Sage Therapeutics
Inder Kaul, Kaul Consulting
Anthony J. Rothschild, University of Massachusetts Medical School
Robert Riesenberg, The Atlanta Center for Medical Research
Abdul J. Sankoh, Sage Therapeutics
Haihong Li, Sage Therapeutics
Robert Lasser, Sage Therapeutics
Charles F. Zorumski, Washington University School of Medicine in St. Louis
David R. Rubinow, University of North Carolina
Steven M. Paul, Washington University School of Medicine in St. Louis
Jeffrey Jonas, Sage Therapeutics
James J. Doherty, Sage Therapeutics
Stephen J. Kanes, Sage Therapeutics

Journal

The New England Journal of Medicine

Publication Date

2019

Volume

381

Issue

10

First Page

903

Last Page

911

Document Type

Open Access Publication

DOI

10.1056/NEJMoa1815981

Rights and Permissions

Gunduz-Bruce, H., Silber, C., Kaul, I., Rothschild, A. J., Riesenberg, R., Sankoh, A. J., . . . Kanes, S. J. (2019). Trial of SAGE-217 in patients with major depressive disorder. New England Journal of Medicine, 381(10), 903-911. doi:10.1056/NEJMoa1815981 Copyright © 2019 Massachusetts Medical Society. All rights reserved.

Recommended Citation

Gunduz-Bruce, Handan; Silber, Christopher; Kaul, Inder; Rothschild, Anthony J.; Riesenberg, Robert; Sankoh, Abdul J.; Li, Haihong; Lasser, Robert; Zorumski, Charles F.; Rubinow, David R.; Paul, Steven M.; Jonas, Jeffrey; Doherty, James J.; and Kanes, Stephen J., "Trial of SAGE-217 in patients with major depressive disorder." The New England Journal of Medicine. 381, 10. 903 - 911. (2019).
https://digitalcommons.wustl.edu/open_access_pubs/8122